The FDA approved midostaurin for patients with newly diagnosed, FLT3 mutation-positive acute myeloid leukemia.
The FDA has approved brigatinib, a dual ALK and EGFR inhibitor, for the treatment of patients with ALK-positive NSCLC who progressed while receiving or are intolerant to crizotinib.
There is high heterogeneity among therapy-persistent LSCs with differences in response to TKI therapy among patients with newly diagnosed CML.
Based on the results of this study, an alternative to HCT should be considered for patients with CK and mutations in TP53 or the RAS pathway.
The US Preventative Services Task Force released a proposed plan for conducting a systematic review of pancreatic cancer screening.
Regorafenib, a multikinase inhibitor, was approved by the FDA for the treatment of hepatocellular carcinoma after prior sorafenib therapy.
Neoadjuvant FLOT followed by surgery improves outcomes among patients with gastric or gastroesophageal junction cancer.
African American men have a higher incidence of preclinical prostate cancer and are more likely to progress to metastatic disease.
Chromosome instability was associated with an increased risk of recurrence and mortality among patients with early-stage NSCLC.
Repression of the microRNA miR-375 may be the primary mechanism underlying the constitutive activation of PDPK1/RPS6KA3 signaling in multiple myeloma.
Although nivolumab did not induce a response in any patients, the presence of tumor-associated macrophages may be a promising treatment avenue for novel combinations.
Pembrolizumab treatment resulted in high ORRs among patients with relapsed/refractory classic Hodgkin lymphoma regardless of previous therapy.
ASCO published a provisional clinical opinion regarding second-line hormonal therapy for men with non-metastatic or minimally symptomatic metastatic CRPC.
The US Food and Drug Administration has sent warning letters to 14 companies for illegally marketing more than 65 products that claim to diagnose, treat, or cure cancer.
TET2 loss may indirectly cause several hematologic malignancies, including myeloid, T cell, and B cell cancers.
Prior chemotherapy was associated with a trend of a greater rate of mortality, SAEs, and AEs causing treatment discontinuation, though these findings were not significant.
Timing might affect the results of an EGFR mutation-frequency circulating tumor DNA (ctDNA) test among patients with advanced NSCLC.
Adding bevacizumab to platinum-based chemotherapy may improve survival among women with recurrent ovarian cancer.
Data suggest that lenalidomide maintenance for 24 months can prolong PFS among elderly patients with DLBCL, but does not improve overall survival.
This study's information can inform policy issues, particularly the collection of patient-reported outcome data and its use in clinical practice.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Warns 14 Companies To Stop Selling Illegal Cancer Treatments
- ASCO Releases Opinion on Hormonal Therapy for Castrate-resistant Prostate Cancer
- Bladder Cancer: Immunotherapies, Combination Therapies, and Current Research
- Pembrolizumab for Advanced Melanoma: Efficacy and Toxicity
- Nivolumab Fails as Single-agent Treatment for Advanced Uterine Leiomyosarcoma